Core Viewpoint - Ademi LLP is investigating RAPT for potential breaches of fiduciary duty and other legal violations related to its transaction with GSK plc [1] Group 1: Transaction Details - RAPT stockholders can choose to receive $58.00 per share, leading to an estimated total equity value of $2.2 billion [2] - RAPT insiders are set to gain significant benefits from change of control arrangements as part of the transaction [2] Group 2: Investigation Focus - The transaction agreement restricts competing offers for RAPT by imposing a substantial penalty if a competing bid is accepted [3] - The investigation will assess whether the RAPT board of directors is meeting their fiduciary responsibilities to all shareholders [3]

Group 1 - GSK has agreed to acquire RAPT Therapeutics for a total valuation of $2.2 billion, with RAPT's stock price rising nearly 64% to $57.40 following the announcement [1] - GSK will pay RAPT shareholders $58.00 per share, leading to an expected upfront investment of $1.9 billion after deducting cash from the acquisition [1] - The acquisition is expected to be completed in the first quarter of 2026 and will be recorded as a business combination by GSK [1] Group 2 - GSK will gain global rights to the ozureprubart project, excluding certain regions in Greater China, and will be responsible for milestone payments and royalties to RAPT's partner, Shanghai Jeyou Pharmaceutical Co. [2] - GSK's Chief Scientific Officer, Tony Wood, highlighted ozureprubart as a promising new therapy with "best-in-class" potential, offering long-lasting protection for food allergy patients with a dosing schedule of every 12 weeks, compared to existing therapies that require biweekly injections [2]

Core Viewpoint - GSK is acquiring RAPT Therapeutics for up to $2.2 billion to enhance its immunology portfolio, focusing on food allergy treatments [1][2]. Group 1: Acquisition Details - GSK will pay $58.00 per share for RAPT, resulting in an aggregate equity value of approximately $2.2 billion, significantly higher than RAPT's closing stock value of $35.10 on January 16 [1]. - The acquisition includes global commercial rights to ozureprubart, a long-acting anti-immunoglobulin E (IgE) prophylactic food allergy candidate, outside of specific Asian markets [2]. Group 2: Product Potential - Ozureprubart is currently in Phase IIb clinical trials and could become a "best-in-class" medication if approved, due to its once-quarterly dosing schedule, unlike other therapies that require more frequent dosing [3]. Group 3: Strategic Focus - GSK is emphasizing immunology as a key growth area, having previously engaged in a $12 billion deal with Hengrui Pharma for immunology and oncology assets [4]. - The company also established a five-year £50 million ($54.3 million) R&D agreement with the University of Cambridge to develop new treatments for immune dysfunction [5]. Group 4: Industry Context - The pharmaceutical industry is facing a significant patent cliff, with potential losses of $230 billion in the US market from 2025 to 2030, prompting companies to seek new growth avenues [6]. - GSK's Chief Scientific Officer highlighted the use of AI-driven early-stage R&D to strengthen its pipeline and mitigate losses from drug patent expirations [7].

Core Viewpoint - RAPT Therapeutics has agreed to be acquired by GSK in a deal valued at approximately $2.2 billion, leading to a significant increase in RAPT's share price [1] Company Summary - RAPT Therapeutics is a biopharmaceutical company that focuses on developing therapies for cancer and other serious diseases [1] - The acquisition by GSK represents a strategic move to enhance GSK's portfolio in the biopharmaceutical sector [1] Financial Summary - The acquisition deal is valued at around $2.2 billion, indicating a strong market interest and valuation for RAPT Therapeutics [1]

Core Insights - Investors anticipate a significant increase in deal activity in 2026 as pharmaceutical companies aim to replenish their pipelines and take advantage of low interest rates [1] Industry Summary - Drug makers are expected to engage in more mergers and acquisitions to enhance their product offerings and ensure future growth [1] - The current low interest rate environment is seen as a favorable condition for financing new deals, encouraging companies to pursue strategic transactions [1]

Group 1: Stock Market Movements - Logitech (LOGI), NetApp (NTAP), and CDW (CDW) saw declines of 6%, 4%, and 2% respectively after Morgan Stanley downgraded all three, citing a "perfect storm" for IT hardware due to the slowest corporate spending in 15 years outside of COVID-19 [4] - The downgrade was influenced by a 4Q CIO survey indicating softer demand, with resellers expecting 30%-60% of customers to cut budgets for PCs, servers, and storage amid rising component prices [4][5] - The hardware down-cycle is expected to last three to five quarters, with CDW downgraded to Equal-Weight (PT $141), Logitech to Underweight (PT $89), and NetApp to Underweight (PT $89) [5] Group 2: NYSE Developments - The New York Stock Exchange (NYSE) is developing a platform for 24/7 trading of tokenized U.S.-listed equities and ETFs using blockchain technology [5][6] - This platform aims to enable instant settlement, dollar-sized orders, and stablecoin-based funding, although the launch date has not been disclosed [6] - The initiative is part of Intercontinental Exchange's (ICE) broader digital strategy, which includes enhancing clearing infrastructure for 24/7 trading and supporting tokenized deposits [7][8] Group 3: Tesla and EV Market - Tesla (TSLA) is expected to benefit from Canada's decision to reduce tariffs on Chinese-made electric vehicles (EVs) from 100% to 6.1%, allowing 49,000 EVs to be imported annually [9][10] - The EV quota may increase to 70,000 within five years, with half reserved for vehicles priced under C$35,000 ($25,192), which does not include Tesla's models [11] - Tesla's largest plant in Shanghai is already equipped to produce a Canada-specific version of its Model Y, which was previously shipped to Canada before the tariff imposition [10]

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of RAPT Therapeutics, Inc. (NASDAQ: RAPT) to GSK plc for $58.00 per share is fair to RAPT shareholders. Halper Sadeh encourages RAPT shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether RAPT and its board of directors violated th ...

Shares of Rapt Therapeutics Inc (NASDAQ:RAPT) rose sharply in pre-market trading after GSK (NYSE:GSK) agreed to acquire the company for $58 per share for an estimated aggregate equity value of $2.2 billion.Rapt Therapeutics shares jumped 63.4% to $57.36 in the pre-market trading session.Here are some other stocks moving in pre-market trading.GainersINVO Fertility Inc (NASDAQ:IVF) gained 418.2% to $4.21 in pre-market trading. Traders circulate unconfirmed rumor that President Trump making fertility treatment ...

Core Viewpoint - RAPT Therapeutics shares surged 63.5% in pre-market trading to $54.4 following the announcement that GlaxoSmithKline will acquire the company for $58 per share, valuing the equity at $2.2 billion, with an expected initial investment of $1.9 billion [1]. Group 1 - RAPT Therapeutics' market capitalization was less than $1 billion before the trading halt on Friday [1]. - The pre-market price of RAPT Therapeutics reached $54.4, reflecting a significant increase of 63.5% [1]. - The acquisition price of $58 per share represents a premium over the previous closing price of $32.19 [1]. Group 2 - The total market value of RAPT Therapeutics is reported at $973 million [2]. - The trading volume in the pre-market session was 430,100 shares [2]. - The stock has a 52-week high of $42.392 and a low of $5.665, indicating significant volatility [2].

Group 1 - GSK announced the acquisition of U.S.-based RAPT Therapeutics for $2.2 billion [1]